arrow
J

Jeng-Shiun Du

kaohsiung medical university
H指数:8
被引数:156

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Targeting lncRNA MALAT1 attenuates lenalidomide resistance via CD38 epigenetic modulation, oxidative stress–mediated cell death, and remodeling of the pro-tumor microenvironment in multiple myeloma

靶向lncRNA MALAT1通过CD38表观遗传调控、氧化应激介导的细胞死亡以及重塑促肿瘤微环境来缓解来那度胺耐药性,在多发性骨髓瘤中发挥作用。

2025-11-010
OAAI
Real World Evidence of Tirabrutinib As a Salvage Treatment in Patients with Relapsed or Refractory Primary Central Nervous System Lymphoma in Taiwan: A Multicenter Study

台湾地区原发性中枢神经系统淋巴瘤复发或难治患者中,Tirabrutinib作为挽救治疗的真实世界证据:一项多中心研究

BLOOD
IF23.1
2024-11-050
PRE
The Cost-Effectiveness Analysis of Transplant-Ineligible Myeloma Patients with Bortezomib plus Thalidomide plus Dexamethasone (VTD) or Bortezomib plus Melphalan plus Prednisolone (VMP) Treatment in Southern Taiwan

台湾南部接受硼替佐米加沙利度胺加地塞米松 (VTD) 或硼替佐米加美法仑加泼尼松龙 (VMP) 治疗的不合格骨髓瘤患者的成本效益分析

2022-01-192
OAAI
Low Geriatric Nutritional Risk Index Is Associated with Poorer Prognosis in Elderly Diffuse Large B-Cell Lymphoma Patients Unfit for Intensive Anthracycline-Containing Therapy: A Real-World Study

老年营养风险指数低与不适合接受含蒽环类药物强化治疗的老年弥漫性大b细胞淋巴瘤患者预后较差相关: 一项真实世界研究

2021-09-1710
OAAI
Progression Risk Score Estimation Based on Immunostaining Data in Oral Cancer Using Unsupervised Hierarchical Clustering Analysis: A Retrospective Study in Taiwan

使用无监督的层次聚类分析基于口腔癌免疫染色数据的进展风险评分估计: 台湾的一项回顾性研究

2021-09-130
OAAI